These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26439132)

  • 1. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
    Sakamoto I; Hirotsu Y; Nakagomi H; Ouchi H; Ikegami A; Teramoto K; Amemiya K; Mochizuki H; Omata M
    Cancer; 2016 Jan; 122(1):84-90. PubMed ID: 26439132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
    Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities between Uptake of Germline
    Hur YM; Mun J; Kim MK; Lee M; Kim YH; Kim SC
    J Korean Med Sci; 2021 Oct; 36(38):e241. PubMed ID: 34609091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
    Pinto P; Peixoto A; Santos C; Rocha P; Pinto C; Pinheiro M; Leça L; Martins AT; Ferreira V; Bartosch C; Teixeira MR
    PLoS One; 2016; 11(8):e0161438. PubMed ID: 27532258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.
    Sugano K; Nakamura S; Ando J; Takayama S; Kamata H; Sekiguchi I; Ubukata M; Kodama T; Arai M; Kasumi F; Hirai Y; Ikeda T; Jinno H; Kitajima M; Aoki D; Hirasawa A; Takeda Y; Yazaki K; Fukutomi T; Kinoshita T; Tsunematsu R; Yoshida T; Izumi M; Umezawa S; Yagata H; Komatsu H; Arimori N; Matoba N; Gondo N; Yokoyama S; Miki Y
    Cancer Sci; 2008 Oct; 99(10):1967-76. PubMed ID: 19016756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.
    Kwon BS; Byun JM; Lee HJ; Jeong DH; Lee TH; Shin KH; Suh DS; Kim KH
    Cancer Res Treat; 2019 Jul; 51(3):941-950. PubMed ID: 30309222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
    PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
    de Oliveira Ferreira C; Carneiro VCG; Araujo Mariz C
    BMC Cancer; 2024 Apr; 24(1):499. PubMed ID: 38641594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of BRCA1 and BRCA2 to ovarian cancer.
    Ramus SJ; Gayther SA
    Mol Oncol; 2009 Apr; 3(2):138-50. PubMed ID: 19383375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
    Candido-dos-Reis FJ; Song H; Goode EL; Cunningham JM; Fridley BL; Larson MC; Alsop K; Dicks E; Harrington P; Ramus SJ; de Fazio A; Mitchell G; Fereday S; Bolton KL; Gourley C; Michie C; Karlan B; Lester J; Walsh C; Cass I; Olsson H; Gore M; Benitez JJ; Garcia MJ; Andrulis I; Mulligan AM; Glendon G; Blanco I; Lazaro C; Whittemore AS; McGuire V; Sieh W; Montagna M; Alducci E; Sadetzki S; Chetrit A; Kwong A; Kjaer SK; Jensen A; Høgdall E; Neuhausen S; Nussbaum R; Daly M; Greene MH; Mai PL; Loud JT; Moysich K; Toland AE; Lambrechts D; Ellis S; Frost D; Brenton JD; Tischkowitz M; Easton DF; Antoniou A; Chenevix-Trench G; Gayther SA; Bowtell D; Pharoah PD; ; ;
    Clin Cancer Res; 2015 Feb; 21(3):652-7. PubMed ID: 25398451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
    McLaughlin JR; Rosen B; Moody J; Pal T; Fan I; Shaw PA; Risch HA; Sellers TA; Sun P; Narod SA
    J Natl Cancer Inst; 2013 Jan; 105(2):141-8. PubMed ID: 23257159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.
    Metcalfe KA; Fan I; McLaughlin J; Risch HA; Rosen B; Murphy J; Bradley L; Armel S; Sun P; Narod SA
    Gynecol Oncol; 2009 Jan; 112(1):68-72. PubMed ID: 19019415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.
    Thompson ER; Rowley SM; Sawyer S; kConfab ; Eccles DM; Trainer AH; Mitchell G; James PA; Campbell IG
    PLoS One; 2013; 8(1):e54772. PubMed ID: 23372765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    Morse CB; Norquist BM; Harrell MI; Agnew KJ; Gray HJ; Urban RR; Garcia RL; Goff BA; Swisher EM
    Gynecol Oncol; 2016 Nov; 143(2):389-392. PubMed ID: 27575909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited cancer syndromes in 220 Italian ovarian cancer patients.
    Carnevali I; Riva C; Chiaravalli AM; Sahnane N; Di Lauro E; Viel A; Rovera F; Formenti G; Ghezzi F; Sessa F; Tibiletti MG
    Cancer Genet; 2019 Sep; 237():55-62. PubMed ID: 31447066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
    Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM
    Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer susceptibility gene mutations in type I and II endometrial cancer.
    Long B; Lilyquist J; Weaver A; Hu C; Gnanaolivu R; Lee KY; Hart SN; Polley EC; Bakkum-Gamez JN; Couch FJ; Dowdy SC
    Gynecol Oncol; 2019 Jan; 152(1):20-25. PubMed ID: 30612635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Killer Cell Dysfunction in Premenopausal
    Haran S; Chindera K; Sabry M; Wilkinson N; Arora R; Zubiak A; Bartlett TE; Evans I; Jones A; Reisel D; Herzog C; Alkasalias T; Newman M; Kim J; Rådestad AF; Gemzell-Danielsson K; Rosenthal AN; Dubeau L; Lowdell MW; Widschwendter M
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population.
    Idogawa M; Mariya T; Tanaka Y; Saito T; Nakase H; Tokino T; Sakurai A
    J Hum Genet; 2024 May; 69(5):231-234. PubMed ID: 38480854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.